TRENTON, N.J.–(BUSINESS WIRE)–Thousands of individuals who are being told they may be eligible for quick and significant compensation from a proposed $6.5 billion bankruptcy settlement offered by Johnson & Johnson (NYSE:JNJ) are being misled, according to other attorneys who represent ovarian cancer victims. “We believe there is an ongoing effort to attract approvals for J&J’s third attempt at bankruptcy from those without a documented and diagnosed claim of ovarian cancer,” says Andy